Adolescent and young adult patients with cancer: A milieu of unique features

Nature Reviews Clinical Oncology

Volumn 12, Issue 8, 2015, Pages 465-480

  Sender, Leonard ^a   Zabokrtsky, Keri B ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTILEUKEMIC AGENT; B RAF KINASE; CHIMERIC ANTIGEN RECEPTOR; BRAF PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AWARENESS; BONE TUMOR; BRAF GENE; BRAIN TUMOR; BREAST CANCER; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER PREVENTION; CANCER RESEARCH; CANCER RISK; CANCER SURVIVAL; CANCER SURVIVOR; CHILDHOOD LEUKEMIA; CLINICAL FEATURE; CLINICAL PRACTICE; CYTOGENETICS; GENE SEQUENCE; GENOME ANALYSIS; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HUMAN; LAW; MEDICAL TECHNOLOGY; MELANOMA; METASTASIS POTENTIAL; MOLECULAR BIOLOGY; PATIENT ADVOCACY; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; PUBLIC HEALTH SERVICE; QUALITY OF LIFE; REVIEW; SURVIVAL RATE; SURVIVAL TIME; T LYMPHOCYTE; TESTIS CANCER; YOUNG ADULT; ATTITUDE TO HEALTH; CLINICAL TRIAL (TOPIC); GENETICS; HEALTH CARE POLICY; IMMUNOTHERAPY; METASTASIS; MUTATION; ORGANIZATION AND MANAGEMENT; PATHOLOGY; PATIENT SELECTION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; RISK FACTOR; SKIN NEOPLASMS; SOCIAL WORK; STATISTICS AND NUMERICAL DATA; SURVIVOR;

ADOLESCENT; ADULT; CLINICAL TRIALS AS TOPIC; DELIVERY OF HEALTH CARE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SERVICES ACCESSIBILITY; HUMANS; IMMUNOTHERAPY; MELANOMA; MUTATION; NEOPLASM METASTASIS; PATIENT ADVOCACY; PATIENT PROTECTION AND AFFORDABLE CARE ACT; PATIENT SELECTION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS B-RAF; RISK FACTORS; SKIN NEOPLASMS; SOCIAL WORK; SURVIVORS; YOUNG ADULT;

EID: 84938216471     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2015.92     Document Type: Review

References (222)

1. Adolescent and Young Adult Oncology Progress Review Group. Closing the gap: Research and care imperatives for adolescents and young adults with cancer. Office of Science Planning & Assessment (OSPA) Library [online], http://planning.cancer.gov/library/AYAO-PRG-Report-2006-FINAL.pdf (2006).
2. Bleyer, A., O'Leary, M., Barr, R. & Ries, L. A. G. (eds) Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975-2000 (National Cancer Institute 2006).
3. Bleyer, A., Albritton, K. H., Barr, R. D., Lewis, I. J. & Sender, L. S. Trailblazers in adolescent and young adult oncology. J. Adolesc. Young Adult Oncol. 1, 13-18 (2011).
4. Australian Institute of Health and Welfare. Cancer in adolescents and young adults in Australia. Australian Institute of Health and Welfare [online], http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=10737420600 (2011).
5. De, P. et al. Candian adolescents and young adults with cancer: Opportunity to improve coordination and level of care. CMAJ 183, E187-E194 (2011).
6. Wu, Q. J. et al. Cancer incidence among adolescents and young adults in urban Shanghai, 1973-2005. PLoS ONE 7, e42607 (2012).
7. Rajani, S., Young, A. J., McGoldrick, D. A., Pearce, D. L. & Sharaf, S. M. The International Charter of Rights for Young People with Cancer. J. Adolesc. Young Adult Oncol. 1, 49-52 (2011).
8. Howlander, N. et al. SEER Cancer Statistics Review (CSR) 1975-2011. Surveillance, Epidemiology, and End Results Program [online], http://seer.cancer.gov/csr/1975-2011/(2014).
9. Bleyer, A. et al. The distinctive biology of cancer in adolescents and young adults. Nat. Rev. Cancer 8, 288-298 (2008).
10. Portell, C. A. & Sweetenham, J. W. Adult lymphoblastic lymphoma. Cancer J. 18, 432-438 (2012).
11. Zelenetz, A. D. et al. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's lymphomas. J. Natl Compr. Canc. Netw. 8, 288-334 (2010).
12. Wilhelm, M. et al. ENCCA WP17-WP7 consensus paper on teenagers and young adults (TYA) with bone sarcomas. Ann. Oncol. 25, 1500-1505 (2014).
13. Keegan, T. H. et al. Impact of breast cancer subtypes on 3-year survival among adolescent and young adult women. Breast Cancer Res. 15, R95 (2013).
14. Tricoli, J. V., Seibel, N. L., Blair, D. G., Albritton, K. & Hayes-Lattin, B. Unique characteristics of adolescent and young adult acute lymphoblastic leukemia, breast cancer, and colon cancer. J. Natl Cancer Inst. 103, 628-635 (2011).
15. Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer statistics, 2014. CA Cancer J. Clin. 64, 9-29 (2014).
16. Heron, M. Deaths: Leading causes for 2010. Natl Vital Stat. Rep. 62, 1-96 (2013).
17. Farber, S. & Diamond, L. K. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N. Engl. J. Med. 238, 787-793 (1948).
18. Hunger, S. P. et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: A report from the Children's Oncology Group. J. Clin. Oncol. 30, 1663-1669 (2012).
19. Pui, C. H. et al. Improved prognosis for older adolescents with acute lymphoblastic leukemia. J. Clin. Oncol. 29, 386-391 (2011).
20. Stock, W. et al. Outcome of adolescents and young adults with acute lymphoblastic leukemia (ALL): A comparison of Children's Cancer Group (CCG) and Cancer and Leukemia Group B (CALGB) regimens [abstract]. Blood 96, 2009 (2000).
21. Boissel, N. et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J. Clin. Oncol. 21, 774-780 (2003).
22. de Bont, J. M. et al. Significant differences in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs. adult protocols in the Netherlands. Leukemia 18, 2032-2035 (2004).
23. Ramanujachar, R. et al. Adolescents with acute lymphoblastic leukaemia: Outcome on UK national paediatric (ALL97) and adult (UKALLX11/E2993) trials. Pediatr. Blood Cancer 48, 254-261 (2007).
24. Stock, W. et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Leukemia Group B studies. Blood 112, 1646-1654 (2008).
25. Coccia, P. F. et al. Adolescent and young adult oncology. Clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 10, 1112-1150 (2012).
26. Gupta, A. A., Edelstein, K., Albert-Green, A. & D'Agostino, N. Assessing information and service needs of young adults with cancer at a single institution. The importance of information on cancer diagnosis, fertility preservation, diet, and exercise. Support. Care Cancer 21, 2477-2484 (2013).
27. Barling, J. A., Stevens, J. A. & Davies, K. M. The reality of hospitalisation: Stories from family members of their hospital experience for adolescents and young adults living with and dying from cancer. Contemp. Nurse 46, 150-160 (2014).
28. Schiffer, C. A. Differences in outcomes in adolescents with acute lymphoblastic leukemia: A consequence of better regimens? Better doctors? Both? J. Clin. Oncol. 21, 760-761 (2003).
29. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00558519?term=C10403&rank=1 (2013).
30. Advani, A. S. et al. Frontline-treatment of acute lymphoblastic leukemia (ALL) in older adolescents and young adults (AYA) using a pediatric regimen is feasible: Toxicity results of the prospective US Intergroup Trial C10403 (Alliance) [abstract]. Blood 122, 3903 (2013).
31. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00075725?term=NCT00075725&rank=1 (2013).
32. Yang, J. J. et al. Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat. Genet. 43, 237-241 (2011).
33. Xu, H. et al. ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia. J. Clin. Oncol. 30, 751-757 (2012).
34. Xu, H. et al. Novel susceptibility variants at 10p12.31-122 for childhood acute lymphoblastic leukemia in ethnically diverse populations. J. Natl Cancer Inst. 105, 733-742 (2013).
35. Radtke, S. et al. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood 121, 5145-5153 (2013).
36. Kapogiannis, B. G. & Mattison, D. R. Adolescents in clinical trials. Clin. Pharmacol. Ther. 84, 655-659 (2008).
37. Nowell, P. C. Discovery of the Philadelphia chromosome: A personal perspective. J. Clin. Invest. 117, 2033-2035 (2007).
38. de Klein, A. et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 300, 765-767 (1982).
39. Schultz, K. R. et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: A Children's Oncology Group study. J. Clin. Oncol. 27, 5175-5181 (2009).
40. Hunger, S. P. Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia. Hematology Am. Soc. Hematol. Educ. Program 2011, 361-365 (2011).
41. Priest, J. R. et al. Philadelphia chromosome positive childhood acute lymphoblastic leukemia. Blood 56, 15-22 (1980).
42. Faderl, S. et al. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk. Lymphoma 36, 263-273 (2000).
43. Harrison, C. J. Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br. J. Haematol. 144, 147-156 (2009).
44. Koo, H. H. Philadelphia chromosome-positive acute lymphoblastic leukemia in childhood. Korean J. Pediatr. 54, 106-110 (2011).
45. Schultz, K. R. et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: A Children's Oncology Group study. J. Clin. Oncol. 27, 5175-5181 (2009).
46. Schultz, K. R. et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. Leukemia 28, 1467-1471 (2014).
47. Lee, H. J., Thompson, J. E., Wang, E. S. & Wetzler, M. Philadelphia chromosome-positive acute lymphoblastic leukemia: Current treatment and future perspectives. Cancer 117, 1583-1594 (2011).
48. Cohen, M. H., Johnson, J. R., Justice, R. & Pazdur, R. FDA drug approval summary: Nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. Oncologist 13, 709-714 (2008).
49. Winter, S. S. et al. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatr. Blood Cancer. http://dx.doi.org/10.1002/pbc.25470.
50. Van Vlierberghe, P. & Ferrando, A. The molecular basis of T cell acute lymphoblastic leukemia. J. Clin. Invest. 122, 3398-3406 (2012).
51. Moorman, A. V. et al. IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia. J. Clin. Oncol. 30, 3100-3108 (2012).
52. Harvey, R. C. et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 115, 5312-5321 (2010).
53. Moorman, A. V. & Harrison, C. J. in Adult acute lymphoblastic leukemia: Biology and treatment. (eds Advani, A. S. & Lazarus, H. M.) 61-76 (Springer Science+Business Media, 2011).
54. Harrison, C. J. Targeting signaling pathways in acute lymphoblastic leukemia: New insights. Hematology Am. Soc. Hematol. Educ. Program 2013, 118-125 (2013).
55. Advani, A. S. Biology and treatment of acute lymphocytic leukemia in adolescents and young adults. Am. Soc. Clin. Oncol. Educ. Book 2013, 285-289 (2013).
56. Mullighan, C. G. et al. Deletion of IKZF1 and prognosis in acute lymphblastic leukemia. N. Engl. J. Med. 360, 470-480 (2009).
57. Kang, H. et al. Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood 115, 1394-1405 (2010).
58. Harvey, R. C. et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: Correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood 116, 4874-4884 (2010).
59. Roberts, K. G. et al. Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J. Clin. Oncol. 32, 3012-3020 (2014).
60. Pui, C. H. et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N. Engl. J. Med. 360, 2730-2741 (2009).
61. Pui, C. H. et al. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: A prospective study. Lancet Oncol. 16, 465-474 (2015).
62. Roberts, K. G. et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N. Engl. J. Med. 371, 1005-1015 (2014).
63. Brayer, J. B. & Pinilla-Ibarz, J. Developing strategies in the immunotherapy of leukemias. Cancer Control 20, 49-59 (2013).
64. CAR T-Cell therapy: Engineering patients' immune cells to treat their cancers. The National Cancer Institute at the National Institute of Health [online], http://www.cancer.gov/cancertopics/research-updates/2013/CAR-T-Cells (2014).
65. Grupp, S. A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509-1518 (2013).
66. Davila, M. L. et al. Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. Int. J. Hematol. 99, 361-371 (2014).
67. Dotti, G., Gottschalk, S., Savoldo, B. & Brenner, M. K. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol. Rev. 257, 107-126 (2014).
68. Fry, T. J. & Mackall, C. L. T-cell adoptive immunotherapy for acute lymphoblastic leukemia. Hematology Am. Soc. Hematol. Educ. Program 2013, 348-353 (2013).
69. Ramos, C. A., Savoldo, B. & Dotti, G. CD19-CAR trials. Cancer J. 20, 112-118 (2014).
70. Xu, X. J., Zhao, H. Z. & Tang, Y. M. Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: A systematic review of phase I clinical trials. Leuk. Lymphoma 54, 255-260 (2013).
71. Davila, M. L. et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra25 (2014).
72. Brentjens, R. J. et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177-ra38 (2013).
73. Kochenderfer, J. N. et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122, 4129-4139 (2013).
74. Cruz, C. R. et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: A phase 1 study. Blood 122, 2965-2973 (2013).
75. Novartis Media Releases. Novartis personalized cell therapy CTL019 receives FDA Breakthrough Therapy designation [online], http://www.novartis.com/newsroom/media-releases/en/2014/1816270.shtml (2014).
76. Nagorsen, D. et al. Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. Leuk. Lymphoma 50, 886-891 (2009).
77. Dijoseph, J. F., Dougher, M. M., Armellino, D. C., Evans, D. Y. & Damle, N. K. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia 21, 2240-2245 (2007).
78. Handgretinger, R. et al. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia 25, 181-184 (2011).
79. Topp, M. S. et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J. Clin. Oncol. 29, 2493-2498 (2011).
80. Amgen News Releases. Amgen receives FDA Breakthrough Therapy designation for investigational BiTE® antibody blinatumomab in acute lymphoblastic leukemia [online], http://www.amgen.com/media/media-pr-detail.jsp?releaseID=1944069 (2014).
81. Kochuparambil, S. T. & Litzow, M. R. Novel antibody therapy in acute lymphoblastic leukemia. Curr. Hematol. Malig. Rep. 9, 165-173 (2014).
82. Rytting, M., Triche, L., Thomas, D., O'Brien, S. & Kantarjian, H. Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia. Pediatr. Blood Cancer 61, 369-372 (2014).
83. Hausauer, A. K., Swetter, S. M., Cockburn, M. G. & Clarke, C. A. Increases in melanoma among adolescent girls and young women in California: Trends by socioeconomic status and UV radiation exposure. Arch. Dermatol. 147, 783-789 (2011).
84. Rigel, D. S. Epidemology of melanoma. Semin. Cutan. Med. Surg. 29, 204-209 (2010).
85. Tavernise, S. Surgeon General calls for action to reduce skin cancer rate. The New York Times [online], http://www.nytimes.com/2014/07/30/science/surgeon-general-calls-for-action-to-reduce-skin-cancer-rate.html?-r=0 (2014).
86. Liu, F. et al. A unique gender difference in early onset melanoma implies that in addition to ultraviolet light exposure other causative factors are important. Pigment Cell Melanoma Res. 26, 128-135 (2013).
87. Schulman, J. M. & Fisher, D. E. Indoor ultraviolet tanning and skin cancer: Health risks and opportunities. Curr. Opin. Oncol. 21, 144-149 (2009).
88. Skin Cancer Foundation. Facts about sunburn and skin cancer [online], http://www.skincancer.org/prevention/sunburn/facts-about-sunburn-and-skin-cancer (2014).
89. Boniol, M., Autier, P., Boyle, P. & Gandini, S. Cutaneous melanoma attributable to sunbed use: Systematic review and meta-analyis. BMJ 345, e4757 (2012).
90. Lazovich, D. et al. Indoor tanning and risk of melanoma: A case-control study in a highly exposed population. Cancer Epidemiol. Biomarkers Prev. 19, 1557-1568 (2010).
91. Green, A. C., Williams, G. M., Logan, V. & Strutton, G. M. Reduced melanoma after regular sunscreen use: Randomized trial follow-up. J. Clin. Oncol. 29, 257-263 (2011).
92. Thieden, E., Philipsen, P. A., Sandby-Møller, J., Heydenreich, J. & Wulf, H. C. Proportion of lifetime UV dose received by children, teenagers and adults based on time-stamped personal dosimetry. J. Invest. Dermatol. 123, 1147-1150 (2004).
93. American Cancer Society. Known and probable human carcinogens [online], http://www.cancer.org/cancer/cancercauses/othercarcinogens/generalinformationaboutcarcinogens/known-and-probable-human-carcinogens (2014).
94. Mancebo, S. E., Hu, J. Y. & Wang, S. Q. Sunscreens: A review of health benefits, regulations, and controversies. Dermatol. Clin. 32, 427-438 (2014).
95. Potente, S., Coppa, K., Williams, A. & Engels, R. Legally brown: Using ethnographic methods to understand sun protection attitudes and behaviours among young Australians 'I didn't mean to get burnt-it just happened!'. Health Educ. Res. 26, 39-52 (2011).
96. Bränström, R. et al. Melanoma risk factors, perceived threat and intentional tanning: An international online survey. Eur. J. Cancer Prev. 19, 216-226 (2010).
97. Knight, J. M., Kirincich, A. N., Farmer, E. R. & Hood, A. F. Awareness of the risks of tanning lamps does not influence behavior among college students. Arch. Dermatol. 138, 1311-1315 (2002).
98. Holman, D. M. & Watson, M. Correlates of intentional tanning among adolescents in the United States: A systematic review of the literature. J. Adolesc. Health 52, S52-S59 (2013).
99. Merten, J. W., Higgins, S., Rowan, A. & Pragle, A. Sun safety knowledge, attitudes, and behaviors among beachgoing adolescents. Am. J. Health Educ. 45, 37-41 (2014).
100. Iannacone, M. R., Youlden, D. R., Baade, P. D., Aitken, J. F. & Green, A. C. Melanoma incidence trends and survival in adolescents and young adults in Queensland, Australia. Int. J. Cancer 136, 603-609 (2015).
101. Hazen, B. P., Bhatia, A. C., Zaim, T. & Brodell, R. T. The clinical diagnosis of early malignant melanoma: Expansion of the ABCD criteria to improve diagnostic sensitivity. Dermatol. Online J. 5, 3 (1999).
102. Abbasi, N. R. et al. Early diagnosis of cutaneous melanoma: Revisiting the ABCD criteria. JAMA 292, 2771-2776 (2004).
103. Titus, L. J. et al. Recent skin self-examination and doctor visits in relation to melanoma risk and tumour depth. Br. J. Dermatol. 168, 571-576 (2013).
104. De Giorgi, V. et al. Skin self-examination and the ABCDE rule in the early diagnosis of melanoma: Is the game over? Br. J. Dermatol. 168, 1370-1371 (2013).
105. Weir, H. K. et al. Melanoma in adolescents and young adults (ages 15-39 years): United States, 1999-2006. J. Am. Acad. Dermatol. 65, S38-S49 (2011).
106. Cordoro, K. M., Gupta, D., Frieden, I. J., McCalmont, T. & Kashani-Sabet, M. Pediatric melanoma: Results of a large cohort study and proposal for modified ABCD detection criteria for children. J. Am. Acad. Dermatol. 68, 913-925 (2013).
107. Long, G. V. et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am. J. Surg. Pathol. 37, 61-65 (2013).
108. Ascierto, P. A. et al. The role of BRAF V600 mutation in melanoma. J. Transl. Med. 10, 85 (2012).
109. Wong, K. K. Recent developments in anti-cancer agents targeting the Ras/Raf/MEK/ERK pathway. Recent Pat. Anticancer Drug Discov. 4, 28-35 (2009).
110. Wellbrock, C. & Hurlstone, A. BRAF as therapeutic target in melanoma. Biochem. Pharmacol. 80, 561-567 (2010).
111. Cantwell-Dorris, E. R., O'Leary, J. J. & Sheils, O. M. BRAFV600E: Implications for carcinogenesis and molecular therapy. Mol. Cancer Ther. 10, 385-394 (2011).
112. Garbe, C., Abusaif, S. & Eigentler, T. K. Vemurafenib. Recent Results Cancer Res. 201, 215-225 (2014).
113. Ribas, A. & Flaherty, K. T. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat. Rev. Clin. Oncol. 8, 426-433 (2011).
114. Flemming, A. Cancer: Targeting mutant BRAF in metastatic melanoma. Nat. Rev. Drug Discov. 9, 841 (2010).
115. Sala, E. et al. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol. Cancer Res. 6, 751-759 (2008).
116. Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599 (2010).
117. Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 63, 809-819 (2010).
118. Basile, K. J., Abel, E. V. & Aplin, A. E. Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells. Oncogene 31, 2471-2479 (2012).
119. Sun, C. et al. Reversible and adaptive resistance to BRAFV600E inhibition in melanoma. Nature 508, 118-122 (2014).
120. Rebecca, V. W. et al. Evaluating melanoma drug response and therapeutic escape with quantitative proteomics. Mol. Cell Proteomics 13, 1844-1854 (2014).
121. Abdel-Wahab, O. et al. Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF-and NRAS-mutant malignancies. Cancer Discov. 4, 538-545 (2014).
122. Jarkowski, A. & Khushalani, N. I. BRAF and beyond: Tailoring strategies for the individual melanoma patient. J. Carcinog. 13, 1 (2014).
123. GlaxoSmithKline Media. Trametinib (Mekinist™) and dabrafenib (Tafinlar™) combination demonstrated overall survival benefit compared to vemurafenib; phase III BRAF V600-mutant metastatic melanoma study stopped early [online], http://www.gsk.com/en-gb/media/press-releases/2014/trametinib-mekinist-and-dabrafenib-tafinlar-combination-demonstrated-overall-survival-benefit-compared-to-vemurafenib-phase-iii-braf-v600-mutant-metastatic-melanoma-study-stopped-early/(2014).
124. Rastrelli, M. et al. Melanoma m1: Diagnosis and therapy. In Vivo 28, 273-285 (2014).
125. Yauch, R. L. & Settleman, J. Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis. Curr. Opin. Genet. Dev. 22, 45-49 (2012).
126. Dutton-Regester, K. & Hayward, N. K. Whole genome and exome sequencing of melanoma: A step toward personlized targeted therapy. Adv. Pharmacol. 65, 399-435 (2012).
127. Perrin, C. et al. Metastatic melanoma: Results of 'classical' second-line treatment with cytotoxic chemotherapies. J. Dermatolog. Treat. 25, 396-400 (2014).
128. Rigel, D. S. & Carucci, J. A. Malignant melanoma. Prevention, early detection, and treatment in the 21st century. CA Cancer J. Clin. 50, 215-236 (2000).
129. Legha, S. S. Current therapy for malignant melanoma. Semin. Oncol. 16, 34-44 (1989).
130. Kirkwood, J. M., Jukic, D. M., Averbook, B. J. & Sender, L. S. Melanoma in pediatric, adolescent, and young adult patients. Semin. Oncol. 36, 419-431 (2009).
131. Mamalis, A., Garcha, M., Jagdeo, J. Targeting the PD-1 pathway: A promising future for the treatment of melanoma. Arch. Dermatol. Res. 306, 511-519 (2014).
132. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
133. Bristol-Myers Squibb Press Releases. Phase 3 first-line melanoma study of nivolumab, an investigational PD-1 checkpoint inhibitor, demonstrates superior overall survival compared to dacarbazine; Study stopped early [online], http://news.bms.com/press-release/phase-3-first-line-melanoma-study-nivolumab-investigational-pd-1-checkpoint-inhibitor (2014).
134. Webster, R. M. & Mentzer, S. E. The malignant melanoma landscape. Nat. Rev. Drug Discov. 13, 491-492 (2014).
135. Kefford, R. et al. Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. Presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting (2014).
136. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
137. Maio, M. et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J. Clin. Oncol. 33, 1191-1196 (2015).
138. Merck's pivotal KEYNOTE-006 study in first-line treatment for advanced melanoma met co-primary endpoints and will be stopped early. Merck [online], http://www.mercknewsroom.com/news-release/oncology-newsroom/mercks-pivotal-keynote-006-study-first-line-treatment-advanced-melano (2015).
139. Philips, G. K. & Atkins, M. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int. Immunol. 27, 39-46 (2015).
140. Shin, D. S. & Ribas, A. The evolution of checkpoint blockade as a cancer therapy: What's here, what's next? Curr. Opin. Immunol. 33, 23-35 (2015).
141. Tsai, K. K. & Daud, A. L. The role of anti-PD-1/PD-L1 agents in melanoma: Progress to date. Drugs 75, 563-575 (2015).
142. Mahoney, K. M., Freeman, G. J. & McDermott, D. F. The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clin. Ther. http://dx.doi.org/10.1016/j.clinthera.2015.02.018
143. Beaupin, L. Are adolescents overlooked in clinical trials? Roswell Park Cancer Institute [online], https://www.roswellpark.org/cancertalk/201305/are-adolescents-overlooked-clinical-trials (2013).
144. Tai, E. et al. Understanding and addressing the lack of clinical trial enrollment among adolescents with cancer. Pediatrics 133, S98-S103 (2014).
145. Fern, L. A., Lewandowski, J. A., Coxon, K. M. & Whelan, J., for the National Cancer Research Institute Teenage and Young Adult Clinical Studies Group UK. Available, accessible, aware, appropriate, and acceptable: A strategy to improve participation of teenagers and young adults in cancer trials. Lancet Oncol. 15, e341-e350 (2014).
146. Unger, J. M. et al. Patient income level and cancer clinical trial participation. J. Clin. Oncol. 31, 536-542 (2013).
147. Unger, J. M. et al. Comparison of survival outcomes among cancer patients treated in and out of clinical trials. J. Natl Cancer Inst. 106, dju002 (2014).
148. Ellis, L. M. et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J. Clin. Oncol. 32, 1277-1280 (2014).
149. Burke, M. E., Albritton, K. & Marina, N. Challenges in the recruitment of adolescents and young adults to cancer clinical trials. Cancer 110, 2385-2393 (2007).
150. Song, P. H., Reiter, K. L., Weiner, B. J., Minasian, L. & McAlearney, A. S. The business case for provider participation in clinical trials research: An application to the National Cancer Institute's community clinical oncology program. Health Care Manage. Rev. 38, 284-294 (2013).
151. Institute of Medicine. Transforming clinical research in the United States: Challenges and opportunities: Workshop summary. The National Academies Press [online], http://www.nap.edu/catalog/12900/transforming-clinical-research-in-the-united-states-challenges-and-opportunities (2010).
152. National Cancer Institute. Clinical trials offer a path to better care for AYAs with cancer [online], http://www.cancer.gov/cancertopics/research/clinical-trials-offer-path-to-better-care-for-ayas (2011).
153. Tai, E., Beaupin, L. & Bleyer, A. Clinical trial enrollment among adolescents with cancer: Supplement overview. Pediatrics 133, S85-S90 (2014).
154. Gupta, A. A. & Indelicato, D. J. Increasing the number of clinical trials available to adolescents diagnosed with cancer. Pediatrics 133, S114-S118 (2014).
155. Kaplan, C. P. et al. Clinical trial discussion, referral, and recruitment: Physician, patient, and system factors. Cancer Causes Control 24, 979-988 (2013).
156. Baer, A. R., Michaels, M., Good, M. J. & Schapira, L. Engaging referring physicians in the clinical trial process. J. Oncol. Pract. 8, e8-e10 (2012).
157. Gribsby, T. J. et al. Attitudes toward cancer clinical trial participation in young adults with a history of cancer and a healthy college student sample: A preliminary investigation. J. Adolesc. Young Adult Oncol. 3, 20-27 (2014).
158. Manne, S. et al. Attitudinal barriers to participation in oncology clinical trials: Factor analysis and correlates of barriers. Eur. J. Cancer Care (Engl.). 24, 28-38 (2015).
159. Manne, S. et al. Knowledge, attitudes, and self-efficacy as predictors of preparedness for oncology clinical trials: A mediational model. Med. Decis. Making 34, 454-463 (2014).
160. Langford, A., Resnicow, K. & An, L. Clinical trial awareness among racial/ethnic minorities in HINTS 2007: Sociodemographic, attitudinal, and knowledge correlates. J. Health Commun. 15, 92-101 (2010).
161. Langford, A. et al. Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute's Community Cancer Centers Program. Cancer 120, 877-884 (2014).
162. Parsons, H. M., Harlan, L. C., Seibel, N. L., Stevens, J. L. & Keegan, T. H. Clinical trial participation and time to treatment among adolescents and young adults with cancer: Does age at diagnosis or insurance make a difference? J. Clin. Oncol. 29, 4045-4053 (2011).
163. Barakat, L. P., Schwartz, L. A., Reilly, A., Deatrick, J. A. & Balis, F. A qualitative study of phase III cancer clinical trial enrollment decision-making: Perspectives from adolescents, young adults, caregivers, and providers. J. Adolesc. Young Adult Oncol. 3, 3-11 (2014).
164. Read, K. et al. Decision-making by adolescents and parents of children with cancer regarding health research participation. Pediatrics 124, 959-965 (2009).
165. Miller, V. A. et al. Adolescent perspectives on phase I cancer research. Pediatr. Blood Cancer 60, 873-878 (2013).
166. Sprague, D., Russo, J., LaVallie, D. L. & Buchwald, D. Barriers to cancer clinical trial participation among American Indian and Alaska Native tribal college students. J. Rural Health 29, 55-60 (2013).
167. Shaw, P. H. et al. Improved clinical trial enrollment in adolescent and young adult (AYA) oncology patients after the establishment of an AYA oncology program uniting pediatric and medical oncology divisions. Cancer 118, 3614-3617 (2012).
168. Stoneham, S. J. et al. Adolescents and young adults with a "rare" cancer: Getting past semantics to optimal care for patients with germ cell tumors. Oncologist 19, 689-692 (2014).
169. Freyer, D. R., Felgenhauer, J. Perentesis, J. & COG Adolescent and Young Adult Oncology Discipline Committee. Children's Oncology Group's 2013 blueprint for research: Adolescent and young adult oncology. Pediatr. Blood Cancer 60, 1055-1058 (2013).
170. Grubbs, S. S. The new National Cancer Institute National Clinical Trials Network. Am. Soc. Clin. Oncol. Educ. Book 2012, 146-148 (2012).
171. Committee on Cancer Clinical Trials and the NCI Cooperative Group Program (eds Nass, S. J., Moses, H. L. & Mendelsohn, J.). A national cancer clinical trials system for the 21st century: Reinvigorating the NCI cooperative group program (The National Academies Press, 2010).
172. Felgenhauer, J. & Hooke, M. C. Regulatory barriers to clinical trial enrollment of adolescent and young adult oncology patients. Pediatrics 133, S119-S122 (2014).
173. Abrams, J. et al. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. Am. Soc. Clin. Oncol. Educ. Book 2014, 71-76 (2014).
174. Gorman, J. R. et al. A diversified recruitment approach incorporating social media leads to research participation among young adult-aged female cancer survivors. J. Adolesc. Young Adult Oncol. 3, 59-65 (2014).
175. Fern, L. & Whelan, J. National Cancer Research Institute Teenage and Young Adult Clinical Studies Group: The United Kingdom approach to research. International perspectives on AYAO, part 4. J. Adolesc. Young Adult Oncol. 2, 161-166 (2013).
176. Denicoff, A. M. et al. The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: Summary and recommendations. J. Oncol. Pract. 9, 267-276 (2013).
177. Epelman, C. L. The adolescent and young adult with cancer: State of the art-psychosocial aspects. Curr. Oncol. Rep. 15, 325-331 (2013).
178. Smith, A. W. et al. Unmet support service needs and health-related quality of life among adolescents and young adults with cancer: The AYA HOPE study. Front. Oncol. 3, 75 (2013).
179. Zebrack B. J. et al. Psychosocial service use and unmet need among recently diagnosed adolescent and young adult cancer patients. Cancer 119, 201-214 (2013).
180. Veloso, A. G. et al. Unmet needs in cancer rehabilitation during the early cancer trajectory-a nationwide patient survey. Acta Oncol. 52, 372-381 (2013).
181. Zebrack, B. J. et al. Psychological distress and unsatisfied need for psychosocial support in adolescent and young adult cancer patients during the first year following diagnosis. Psychooncology 23, 1267-1275 (2014).
182. D'Agostino, N. M. & Edelstein, K. Psychosocial challenges and resource needs of young adult cancer survivors: Implications for program development. J. Psychosoc. Oncol. 31, 585-600 (2013).
183. Park, C. L., Wortmann, J. H., Hale, A. E., Cho, D. & Blank, T. O. Assessing quality of life in young adult cancer survivors: Development of the Survivorship-Related Quality of Life scale. Qual. Life Res. 23, 2213-2224 (2014).
184. Rabin, C., Simpson, N., Morrow, K. & Pinto, B. Intervention format and delivery preferences among young adult cancer survivors. Int. J. Behav. Med. 20, 304-310 (2013).
185. Nathan, P. C. et al. Family physician preferences and knowledge gaps regarding the care of adolescent and young adult survivors of childhood cancer. J. Cancer Surviv. 7, 275-282 (2013).
186. Hauken, M. A., Larsen, T. M. & Holsen, I. Meeting reality: Young adult cancer survivors' experiences of reentering everyday life after cancer treatment. Cancer Nurs. 36, E17-E26 (2013).
187. Wiener, L., Zadeh, S., Wexler, L. H. & Pao, M. When silence is not golden: Engaging adolescents and young adults in discussions around end-of-life care choices. Pediatr. Blood Cancer 60, 715-718 (2013).
188. Zadeh, S., Pao, M. & Wiener, L. Opening end-of-life discussions: How to introduce Voicing My CHOiCES™, an advance care planning guide for adolescents and young adults. Palliat. Support. Care http://dx.doi.org/10.1017/S1478951514000054 (2014).
189. Nass, S. J. & Patlak, M. (eds) Identifying and addressing the needs of adolescents and young adults with cancer: Workshop summary (2013). The National Academies Press [online], http://www.nap.edu/catalog/18547/identifying-and-addressing-the-needs-of-adolescents-and-young-adults-with-cancer (2013).
190. Callahan, S. T. & Cooper, W. O. Uninsurance and health care access among young adults in the United States. Pediatrics 116, 88-95 (2005).
191. Bleyer, A., Budd, T. & Montello, M. Adolescents and young adults with cancer: The scope of the problem and criticality of clinical trials. Cancer 107, 1645-1655 (2006).
192. Park, E. R. et al. Childood Cancer Survivor Study participants' perceptions and knowledge of health insurance coverage: Implications for the Affordable Care Act. J. Cancer Surviv. 6, 251-259 (2012).
193. Wich, L. G. et al. Impact of socioeconomic status and sociodemographic factors on melanoma presentation among ethnic minorities. J. Community Health 36, 461-468 (2011).
194. Smith, E. C., Ziogas, A. & Anton-Culver, H. Delay in surgical treatment and survival after breast cancer diagnosis in young women by race/ethnicity. JAMA Surg. 148, 516-523 (2013).
195. Smith, E. C., Ziogas, A. & Anton-Culver, H. Association between insurance and socioeconomic status and risk of advanced stage Hodgkin lymphoma in adolescents and young adults. Cancer 118, 6179-6187 (2012).
196. Niu, X., Roche, L. M., Pawlish, K. S. & Henry, K. A. Cancer survival disparities by health insurance status. Cancer Med. 2, 403-411 (2013).
197. Smith, A. W. et al. Health-related quality of life of adolescent and young adult patients with cancer in the United States: The Adolescent and Young Adult Health Outcomes and Patient Experience study. J. Clin. Oncol. 31, 2136-2145 (2013).
198. Freyer, D. R. Transition of care for young adult survivors of childhood and adolescent cancer: Rationale and approaches. J. Clin. Oncol. 28, 4810-4818 (2010).
199. Kirchhoff, A. C., Lyles, C. R., Fluchel, M., Wright, J. & Leisenring, W. Limitations in health care access and utilization among long-term survivors of adolescent and young adult cancer. Cancer 118, 5964-5972 (2012).
200. Aizer, A. A. et al. Cancer-specific outcomes among young adults without health insurance. J. Clin. Oncol. 32, 2025-2030 (2014).
201. US Department of Health & Human Services. Young adult coverage [online], http://www.hhs.gov/healthcare/rights/youngadults/(2014).
202. US Department of Health & Human Services. Preventive services covered under the Affordable Care Act [online], http://www.hhs.gov/healthcare/facts/factsheets/2010/07/preventive-services-list.html#CoveredPreventiveServicesforAdults (2012).
203. Guy, G. P. et al. Estimating the health and economic burden of cancer among those diagnosed as adolescents and young adults. Health Aff. (Millwood) 33, 1024-1031 (2014).
204. Arnett, J. J. Emerging adulthood. A theory of development from the late teens through the twenties. Am. Psychol. 55, 469-480 (2000).
205. The National Collaborating Centre for Cancer. Improving outcomes in children and young people with cancer. The National Institute for Health and Clinical Excellence [online], http://www.nice.org.uk/guidance/csgcyp/resources/improving-outcomes-in-children-and-young-people-with-cancer-manual-update-2 (2005).
206. Zebrack, B., Mathews-Bradshaw, B., Siegel, S. & LIVESTRONG Young Adult Alliance. Quality cancer care for adolescents and young adults: A position statement. J. Clin. Oncol. 28, 4862-4867 (2010).
207. Hayes-Lattin, B., Mathews-Bradshaw, B. & Siegel, S. Adolescent and young adult oncology training for health professionals: A position statement. J. Clin. Oncol. 28, 4858-4861 (2010).
208. Ward, E., DeSantis, C., Robbins, A., Kohler, B. & Jemal, A. Childhood and adolescent cancer statistics, 2014. CA Cancer J. Clin. 64, 83-103 (2014).
209. Mulcahy Levy, J. M. et al. Late effects of total body irradiation and hematopoietic stem cell transplant in children under 3 years of age. Pediatr. Blood Cancer 60, 700-704 (2013).
210. Wolfe, K. R. et al. Executive functions and social skills in survivors of pediatric brain tumor. Child Neuropsycol. 19, 370-384 (2013).
211. McClellan, W. et al. Understanding the functional late effects and informational needs of adult survivors of childhood cancer. Oncol. Nurs. Forum 40, 254-262 (2013).
212. Butler, R. W. et al. Interventions to improve neuropsychological functioning in childhood cancer survivors. Dev. Disabil. Res. Rev. 14, 251-258 (2008).
213. Lange, D. D., Wong, A. W., Strauser, D. R. & Wagner, S. Vocational identity, positive affect, and career thoughts in a group of young adult central nervous system cancer survivors. Int. J. Rehabil. Res. 37, 297-301 (2014).
214. Khan, F., Amatya, B., Drummond, K. & Galea, M. Effectiveness of integrated multidisciplinary rehabilitation in primary brain cancer survivors in an Australian community cohort: A controlled clinical trial. J. Rehabil. Med. 46, 754-760 (2014).
215. Schulte, F., Vannatta, K. & Barrera, M. Social problem solving and social performance after a group social skills intervention for childhood brain tumor survivors. Psychooncology 23, 183-189 (2014).
216. Rodgers, S. P., Trevino, M., Zawaski, J. A., Gaber, M. W. & Leasure, J. L. Neurogenesis, exercise, and cognitive late effects of pediatric radiotherapy. Neural Plast. 2013, 698528 (2013).
217. Mulder, R. L., Hudson, M. M., Skinner, R. & Kremer, L. C. Health problems in survivors of childhood cancer: The need for international collaboration in long-term follow-up care. Future Oncol. 9, 1667-1670 (2013).
218. Han, J. W. et al. Increasing and worsening late effects in childhood cancer survivors during follow-up. J. Korean Med. Sci. 28, 755-762 (2013).
219. CureSearch Children's Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers [online], http://www.survivorshipguidelines.org/pdf/LTFUGuidelines.pdf (2008).
220. Essig, S. et al. Risk of late effects of treatment in children newly diagnosed with standard-risk acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study cohort. Lancet Oncol. 15, 841-851 (2014).
221. Kwak, M. et al. Prevalence and predictors of post-traumatic stress symptoms in adolescent and young adult cancer survivors: A 1-year follow-up study. Psychooncology 22, 1798-1806 (2013).
222. Gallagher, J. DNA project 'to make UK world genetic research leader'. BBC News [online], http://www.bbc.com/news/health-28488313 (2015).